Desai Meena P, Bhanuprakash K V, Khatkhatay M Ikram, Donde Uday M
Division of Molecular Immunodiagnostics, National Institute for Research in Reproductive Health, Mumbai, India.
J Clin Lab Anal. 2007;21(2):55-60. doi: 10.1002/jcla.20166.
This study characterizes age-related changes in bone turnover markers in relation to ovarian hormones. The data (N = 236) were divided into 5-year age bands and three groups: premenopausal (Group I, N = 139), perimenopausal (Group II, N = 30), and postmenopausal (Group III, N = 67). Age-related increases in mean parathyroid hormone (PTH), osteocalcin (OC), and collagen telopeptide (CTx) levels were observed. Women in Group II (N = 37) with osteopenia had lower levels of E1G (P<0.001) with normal FSH levels as compared to 50 women in the same group with normal bone mineral density (BMD). Their mean OC levels were reduced (P<0.05) and CTx levels were significantly elevated (P<0.01). The mean E1G levels were significantly lower (P<0.001) and mean CTx levels were significantly higher (P<0.001) in 30 perimenopausal women (Group II) compared to premenopausal women. In 28 postmenopausal women (group III) the mean BMD levels and E1G were significantly lower (P<0.001) with elevated FSH levels (P<0.001). Increased CTx levels (P<0.0001) reflected a higher rate of bone resorption. These observations suggest that perimenopausal women with low E1G, elevated FSH should be screened for osteoporosis, and it may be valid to combine simultaneous measurements of bone turnover markers with ovarian hormones when screening women at risk for osteoporosis.
本研究描述了与卵巢激素相关的骨转换标志物的年龄相关变化。数据(N = 236)被分为5岁年龄组和三组:绝经前(第一组,N = 139)、围绝经期(第二组,N = 30)和绝经后(第三组,N = 67)。观察到甲状旁腺激素(PTH)、骨钙素(OC)和胶原末端肽(CTx)水平随年龄增长而升高。与同一组中50名骨密度(BMD)正常的女性相比,第二组中37名患有骨质减少的女性E1G水平较低(P<0.001),促卵泡激素(FSH)水平正常。她们的平均OC水平降低(P<0.05),CTx水平显著升高(P<0.01)。与绝经前女性相比,30名围绝经期女性(第二组)的平均E1G水平显著降低(P<0.001),平均CTx水平显著升高(P<0.001)。在28名绝经后女性(第三组)中,平均BMD水平和E1G显著降低(P<0.001),FSH水平升高(P<0.001)。CTx水平升高(P<0.0001)反映了更高的骨吸收速率。这些观察结果表明,对于E1G水平低、FSH升高的围绝经期女性应进行骨质疏松症筛查,并且在筛查骨质疏松症高危女性时,将骨转换标志物与卵巢激素同时测量可能是有效的。